Vir Biotechnology (VIR) EBITDA (2018 - 2026)

Vir Biotechnology's EBITDA history runs 9 years deep, the most recent figure standing at -$132.3 million for Q1 2026.

• In Q1 2026, EBITDA rose 5.2% year-over-year to -$132.3 million; the TTM figure through Mar 2026 stood at -$472.1 million (up 27.0% YoY), while the FY2025 annual figure was -$479.3 million, up 18.37% from the prior year.
• EBITDA came in at -$132.3 million for Q1 2026 at Vir Biotechnology, down from -$47.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.0 billion in Q1 2022 to a low of -$231.3 million in Q3 2024.
• A 5-year average of -$61.8 million and a median of -$139.5 million in 2025 frame the typical range for EBITDA.
• On a YoY basis, EBITDA climbed as much as 739.1% in 2022 and fell as far as 469.11% in 2022.
• Vir Biotechnology's EBITDA stood at -$150.5 million in 2022, then gained by 7.63% to -$139.0 million in 2023, then increased by 15.73% to -$117.2 million in 2024, then jumped by 59.09% to -$47.9 million in 2025, then plunged by 176.06% to -$132.3 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$132.3 million, -$47.9 million, and -$173.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison